An electronic switching element (1) which comprises, in this sequence, a first electrode (16), a molecular layer (18) bonded to a substrate, and a second electrode (20), where the molecular layer essentially consists of compounds of the formula I indicated in claim 1, in which a mesogenic radical is bonded to the substrate via a spacer group (Sp) by means of an anchor group (G), is suitable for the production of components (1) as memristive device for digital information storage.

An electronic switching element (1) which comprises, in this sequence, a first electrode (16), a molecular layer (18) bonded to a substrate, and a second electrode (20), where the molecular layer essentially consists of compounds of the formula I indicated in claim 1, in which a mesogenic radical is bonded to the substrate via a spacer group (Sp) by means of an anchor group (G), is suitable for the production of components (1) as memristive device for digital information storage.

The invention relates to terpene-derived acids and esters thereof as well as to processes for synthesizing them.

The invention relates to terpene-derived acids and esters thereof as well as to processes for synthesizing them.

The invention relates to terpene-derived acids and esters thereof as well as to processes for synthesizing them.

A PEG linker as represented by formula (I), wherein n and m are respectively an integer from 1 to 7, providing the PEG linker with 1 to 49 linking sites. A ligand drug conjugate as represented by formula (II). The conjugate uses the PEG linker to increase a drug loading capacity and drug loading diversity, thereby improving pharmaceutical efficacy.

Y1-PEG1-{R.sup.1-PEG2-{Y4}.sub.n}.sub.m(I)

TM-{R.sup.2-PEG1-{R.sup.1-PEG2-{R.sup.3-A-drug}.sub.n}.sub.m}.sub.l(II)

A PEG linker as represented by formula (I), wherein n and m are respectively an integer from 1 to 7, providing the PEG linker with 1 to 49 linking sites. A ligand drug conjugate as represented by formula (II). The conjugate uses the PEG linker to increase a drug loading capacity and drug loading diversity, thereby improving pharmaceutical efficacy.

Y1-PEG1-{R.sup.1-PEG2-{Y4}.sub.n}.sub.m(I)

TM-{R.sup.2-PEG1-{R.sup.1-PEG2-{R.sup.3-A-drug}.sub.n}.sub.m}.sub.l(II)

Provided herein are methods and compositions for chemical mechanical polishing (CMP) of metals. The present methods and compositions involve the use of a corrosion inhibitor having the general formula C.sub.mH.sub.2m+1(OCH.sub.2CH.sub.2).sub.n-L-R in the CMP slurry composition, where m is an integer between 6 and 11, inclusive of end points, and n is an integer greater than or equal to 6, L is a bond, O, S, R.sup.1, SR.sup.1, or OR.sup.1, where R.sup.1 is a C.sub.1-4 alkylene; and R is an anionic group. The present methods and compositions can be used to achieve a high metal removal rate, while effectively inhibiting metal corrosion during CMP, and are particularly useful for CMP of cobalt (Co).

Provided herein are methods and compositions for chemical mechanical polishing (CMP) of metals. The present methods and compositions involve the use of a corrosion inhibitor having the general formula C.sub.mH.sub.2m+1(OCH.sub.2CH.sub.2).sub.n-L-R in the CMP slurry composition, where m is an integer between 6 and 11, inclusive of end points, and n is an integer greater than or equal to 6, L is a bond, O, S, R.sup.1, SR.sup.1, or OR.sup.1, where R.sup.1 is a C.sub.1-4 alkylene; and R is an anionic group. The present methods and compositions can be used to achieve a high metal removal rate, while effectively inhibiting metal corrosion during CMP, and are particularly useful for CMP of cobalt (Co).

Provided herein are various oxa acids having respective molecular weights and hydrophile-lipophile balances both different from each other. A compound having a structure represented by the following formula (1) or (2) is used:

##STR00001##